AbbVie Inc (ABBV) surpasses revenue expectations with robust performance in immunology and neuroscience, while navigating challenges in aesthetics and biosimilar competition.
AbbVie provided an optimistic outlook for 2025, with an adjusted EPS guidance range of $12.12 to $12.32 and total net revenues expected to reach $59 billion. The company anticipates significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback